Skip to main content

Advertisement

SpringerLink
Log in

Checkpointinhibitoren

Welchen Nutzen haben Immuntherapien beim kolorektalen Karzinom?

  • Fortbildung
  • Published:
Gastro-News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

© Springer Medizin Verlag 2019

2

© mod. nach [5]

Literatur

  1. Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibodyincancer. N Engl J Med. 2012;366:2443-54

  2. Le DT et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-20

  3. Le DT et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsa- tellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38:11-9

  4. Andre T et al. Nivolumab plus low-dose ipilimumab in previously trea- ted patients with microsatellite instability-high/ mismatch repair-deficient metastatic colorectal cancer: 4-yearfollow-upfrom CheckMate 142. Ann Oncol. 2022;33:1052-60

  5. Andre T et al. Pembrolizumab in microsatel- lite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207-18

  6. Lenz HJ et al. First-line Nivolu- mab plus low-dose Ipilimumab for microsatellite instability-high/mismatch repair-deficient meta- static colorectal cancer: the phase II checkmate 142 study. J Clin Oncol. 2022;40:161-70

  7. Antoniotti C et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022;23:876-87

  8. Mettu NB et al. Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: arandomized clinical trial. JAMA Netw Open. 2022;5:e2149040

  9. Cercek A et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363-76

  10. Papke DJ Jr et al. Prevalence of mismatch-repair deficiency in rectal adenocarci- nomas. N Engl J Med. 2022;387:1714-16

  11. Chalabi M et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage coloncancers. Nat Med. 2020;26:566-76

  12. Chalabi M et al. Neoadjuvant immune checkpoint inhibition in locally advanced MMR- deficient colon cancer: the NICIE-2 study. Ann Oncol. 2022;33(suppl_7):S808-69 (LBA7)

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik, Krankenhaus St. Joseph-Hospital Bremen, Schwachhauser Heerstraße 54, 28209, Bremen, Germany

    Christian Peter Pox (Chefarzt Medizinische Klinik)

Authors
  1. Christian Peter Pox
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Peter Pox.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pox, C. Welchen Nutzen haben Immuntherapien beim kolorektalen Karzinom?. Gastro-News 10, 41–44 (2023). https://doi.org/10.1007/s15036-023-3283-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15036-023-3283-2

Search

Navigation